Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Operating Income: 2020-2025

Historic Operating Income for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to -$26.2 million.

  • Silence Therapeutics' Operating Income rose 12.51% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 1.45%. This contributed to the annual value of -$63.3 million for FY2024, which is 1.65% up from last year.
  • Per Silence Therapeutics' latest filing, its Operating Income stood at -$26.2 million for Q3 2025, which was down 9.52% from -$24.0 million recorded in Q2 2025.
  • Silence Therapeutics' Operating Income's 5-year high stood at -$4.4 million during Q4 2024, with a 5-year trough of -$30.0 million in Q3 2024.
  • Its 3-year average for Operating Income is -$18.5 million, with a median of -$16.5 million in 2023.
  • In the last 5 years, Silence Therapeutics' Operating Income skyrocketed by 73.63% in 2024 and then plummeted by 409.03% in 2025.
  • Over the past 5 years, Silence Therapeutics' Operating Income (MRQ) stood at -$15.2 million in 2021, then rose by 15.32% to -$12.9 million in 2022, then dropped by 28.39% to -$16.5 million in 2023, then soared by 73.63% to -$4.4 million in 2024, then tumbled by 503.03% to -$26.2 million in 2025.
  • Its Operating Income was -$26.2 million in Q3 2025, compared to -$24.0 million in Q2 2025 and -$28.4 million in Q1 2025.